US
Interested in our medication-supported weight-loss programme?
Weight-loss medications
Evidence-based guidance on weight-loss medications including GLP-1 receptor agonists like Wegovy, Ozempic, and Mounjaro. Find reliable information on efficacy, side effects, NHS availability, and how these medications work as part of a balanced approach to weight loss. Our content is developed by healthcare professionals and nutritionists to support informed decisions about medication-assisted weight loss in the UK.
Weight-loss medications
The Wegovy pill vs Foundayo: which oral GLP-1 medication is better for weight loss?
Wegovy pill vs Foundayo: 13.6% vs 11.2% average weight loss in trials. Wegovy pill needs an empty stomach; Foundayo can be taken any time.
Weight-loss medications
Oral weight-loss medications in the UK: a 2026 guide to the Wegovy pill, Foundayo, and Rybelsus
Three oral GLP-1 weight-loss pills compared. Wegovy pill (13.6%) and Foundayo (11.2%) expected in UK late 2026 and 2027; Rybelsus available now for type 2.
Weight-loss medications
Foundayo (orforglipron): what it is, how it works, and when it’s coming to the UK
Foundayo (orforglipron) is a daily GLP-1 pill for weight loss with no fasting requirements. FDA-approved April 2026. Average weight loss 11.2% at 72 weeks.
Weight-loss medications
Retatrutide vs Wegovy: which works better for weight loss?
Retatrutide produced 28.7% weight loss in trials vs Wegovy 7.2 mg's 20.7%. Retatrutide isn't UK-approved yet; Wegovy is the current option.
Weight-loss medications
Retatrutide side effects: what the trials show and how to manage them
Retatrutide's main side effects in trials: nausea (43%), heart rate increase of ~6.7 bpm, and dysesthesia (20.9%) at the 12 mg dose. Not yet UK-approved.
Weight-loss medications
Retatrutide vs Mounjaro
In trials, retatrutide reached 28.7% weight loss vs Mounjaro's 22.5%. Retatrutide isn't UK-approved yet, so Mounjaro is the current option.
Weight-loss medications
CagriSema vs Mounjaro: how they compare on weight loss, side effects, and UK availability
Mounjaro produced more weight loss than CagriSema in REDEFINE 4: 25.5% vs 23.0% over 84 weeks. Only Mounjaro is licensed and available in the UK.
Weight-loss medications
What is CagriSema? A UK guide to Novo Nordisk’s new weight-loss injection
CagriSema: 22.7% weight loss in REDEFINE 1, the highest for any Novo Nordisk obesity drug. Lost head-to-head to Mounjaro. Not yet UK-approved.
Weight-loss medications
When will CagriSema be available in the UK?
CagriSema isn't yet available in the UK. No MHRA filing as of May 2026. Private launch likely 2026-2027, NHS access from 2028.
Wegovy compatibility
Can you take Wegovy with rheumatoid arthritis?
You can take Wegovy with rheumatoid arthritis. Find out how it interacts with RA medications and why weight loss may improve disease activity.
As seen on
As seen on
